Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology.

[1]  J. Omens,et al.  Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury. , 2007, American journal of physiology. Heart and circulatory physiology.

[2]  D. Roberts,et al.  Sphingosine-1-phosphate initiates rapid retraction of pseudopodia by localized RhoA activation. , 2007, Cellular signalling.

[3]  T. Hla,et al.  Induction of Vascular Permeability by the Sphingosine-1-Phosphate Receptor–2 (S1P2R) and its Downstream Effectors ROCK and PTEN , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[4]  M. Tani,et al.  Lack of sphingosine 1-phosphate-degrading enzymes in erythrocytes. , 2007, Biochemical and biophysical research communications.

[5]  C. Heeschen,et al.  The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1‐phosphate receptor 1 , 2007, Journal of cellular biochemistry.

[6]  E. Goetzl,et al.  Cutting Edge: Alternative Signaling of Th17 Cell Development by Sphingosine 1-Phosphate1 , 2007, The Journal of Immunology.

[7]  J. Cyster,et al.  Promotion of Lymphocyte Egress into Blood and Lymph by Distinct Sources of Sphingosine-1-Phosphate , 2007, Science.

[8]  R. Proia,et al.  Deafness and Stria Vascularis Defects in S1P2 Receptor-null Mice* , 2007, Journal of Biological Chemistry.

[9]  M. Gräler,et al.  Erythrocytes store and release sphingosine 1‐phosphate in blood , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  T. Hla,et al.  Immunosuppressive and Anti-angiogenic Sphingosine 1-Phosphate Receptor-1 Agonists Induce Ubiquitinylation and Proteasomal Degradation of the Receptor* , 2007, Journal of Biological Chemistry.

[11]  B. Levkau,et al.  The Sphingosine-1-Phosphate Analogue FTY720 Reduces Atherosclerosis in Apolipoprotein E–Deficient Mice , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[12]  V. Brinkmann,et al.  FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis , 2007, Expert opinion on investigational drugs.

[13]  J. Stein,et al.  FTY720 Ameliorates Th1-Mediated Colitis in Mice by Directly Affecting the Functional Activity of CD4+CD25+ Regulatory T Cells1 , 2007, The Journal of Immunology.

[14]  D. Herr,et al.  Sphingosine 1-Phosphate (S1P) Signaling Is Required for Maintenance of Hair Cells Mainly via Activation of S1P2 , 2007, The Journal of Neuroscience.

[15]  S. Payne,et al.  The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. , 2007, Blood.

[16]  M. Kondo,et al.  Sphingosine 1-Phosphate Causes Airway Hyper-Reactivity by Rho-Mediated Myosin Phosphatase Inactivation , 2007, Journal of Pharmacology and Experimental Therapeutics.

[17]  G. Assmann,et al.  FTY720, a Synthetic Sphingosine 1 Phosphate Analogue, Inhibits Development of Atherosclerosis in Low-Density Lipoprotein Receptor–Deficient Mice , 2007, Circulation.

[18]  E. Goetzl,et al.  Distinctive T Cell-suppressive Signals from Nuclearized Type 1 Sphingosine 1-Phosphate G Protein-coupled Receptors* , 2007, Journal of Biological Chemistry.

[19]  Michael D. Davis,et al.  Synthesis and biological evaluation of γ-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists , 2007 .

[20]  T. Ohmori,et al.  Essential Roles of Sphingosine 1‐Phosphate/S1P1 Receptor Axis in the Migration of Neural Stem Cells Toward a Site of Spinal Cord Injury , 2007, Stem cells.

[21]  J. Chun,et al.  Sphingosine-1-Phosphate Stimulates the Functional Capacity of Progenitor Cells by Activation of the CXCR4-Dependent Signaling Pathway via the S1P3 Receptor , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[22]  J. Chun,et al.  A growing family of receptor genes for lysophosphatidic acid (LPA) and other lysophospholipids (LPs) , 2007, Cell Biochemistry and Biophysics.

[23]  Y. Banno,et al.  Exogenous sphingosine 1-phosphate and sphingosine kinase activated by endothelin-1 induced myometrial contraction through differential mechanisms. , 2007, American journal of physiology. Cell physiology.

[24]  V. Brinkmann,et al.  FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs. , 2006, International immunopharmacology.

[25]  M. Salvadori,et al.  FTY720 versus MMF with Cyclosporine in de novo Renal Transplantation: A 1‐Year, Randomized Controlled Trial in Europe and Australasia , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  S. Milstien,et al.  Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. , 2006, Biochimica et biophysica acta.

[27]  R. Proia,et al.  Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism , 2006, The Journal of experimental medicine.

[28]  M. Gräler,et al.  Comparative quantification of sphingolipids and analogs in biological samples by high-performance liquid chromatography after chloroform extraction. , 2006, Analytical biochemistry.

[29]  Shwu-Fan Ma,et al.  Transactivation of Sphingosine 1-Phosphate Receptors Is Essential for Vascular Barrier Regulation , 2006, Journal of Biological Chemistry.

[30]  S. Allouche,et al.  Tracking the opioid receptors on the way of desensitization. , 2006, Cellular signalling.

[31]  E. Wolpert,et al.  Pharmacologic manipulation of sphingosine kinase in retinal endothelial cells: implications for angiogenic ocular diseases. , 2006, Investigative ophthalmology & visual science.

[32]  M. Idzko,et al.  Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. , 2006, The Journal of clinical investigation.

[33]  N. Gray,et al.  A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. , 2006, Chemistry & biology.

[34]  Stephen C. Jones,et al.  Erratum: CD4+ T-cell memory: Generation and multi-faceted roles for CD4+ T cells in protective immunity to influenza (Immunological Reviews (2006) 211, (8-22)) , 2006 .

[35]  K. Murthy,et al.  Characterization of S1P1 and S1P2 receptor function in smooth muscle by receptor silencing and receptor protection. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[36]  Eugenia Wang,et al.  Dual Roles of Tight Junction-associated Protein, Zonula Occludens-1, in Sphingosine 1-Phosphate-mediated Endothelial Chemotaxis and Barrier Integrity* , 2006, Journal of Biological Chemistry.

[37]  K. Ley,et al.  Sphingosine-1 Phosphate Prevents Monocyte/Endothelial Interactions in Type 1 Diabetic NOD Mice Through Activation of the S1P1 Receptor , 2006, Circulation research.

[38]  S. Iwai,et al.  Use of Sphingosine-1-Phosphate 1 Receptor Agonist, KRP-203, in Combination with a Subtherapeutic Dose of Cyclosporine A for Rat Renal Transplantation , 2006, Transplantation.

[39]  J. Stypmann,et al.  High-Density Lipoproteins and Their Constituent, Sphingosine-1-Phosphate, Directly Protect the Heart Against Ischemia/Reperfusion Injury In Vivo via the S1P3 Lysophospholipid Receptor , 2006, Circulation.

[40]  U. V. von Andrian,et al.  Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration. , 2006, The New England journal of medicine.

[41]  Ludwig Kappos,et al.  Oral fingolimod (FTY720) for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[42]  N. Pyszczynski,et al.  Physiologically Based Pharmacokinetic Modeling of FTY720 (2-Amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in Rats After Oral and Intravenous Doses , 2006, Drug Metabolism and Disposition.

[43]  S. Oshima,et al.  FTY720 suppresses CD4+CD44highCD62L- effector memory T cell-mediated colitis. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[44]  J. Kovarik,et al.  FTY720: Placebo‐Controlled Study of the Effect on Cardiac Rate and Rhythm in Healthy Subjects , 2006, Journal of clinical pharmacology.

[45]  J. Badimón,et al.  The role of high-density lipoprotein cholesterol in the prevention and possible treatment of cardiovascular diseases. , 2006, Current molecular medicine.

[46]  Ian Parker,et al.  Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo , 2006, Nature chemical biology.

[47]  Stephen C. Jones,et al.  CD4+ T‐cell memory: generation and multi‐faceted roles for CD4+ T cells in protective immunity to influenza , 2006, Immunological reviews.

[48]  V. Brinkmann,et al.  Pulmonary and vascular pharmacology of sphingosine 1-phosphate. , 2006, Current opinion in pharmacology.

[49]  K. Murphy,et al.  Th17: an effector CD4 T cell lineage with regulatory T cell ties. , 2006, Immunity.

[50]  M. Montagnani,et al.  Endothelin-1: the yin and yang on vascular function. , 2006, Current medicinal chemistry.

[51]  Naděžda Brdičková,et al.  CD69 acts downstream of interferon-α/β to inhibit S1P1 and lymphocyte egress from lymphoid organs , 2006, Nature.

[52]  N. Rouach,et al.  S1P inhibits gap junctions in astrocytes: involvement of Gi and Rho GTPase/ROCK , 2006, The European journal of neuroscience.

[53]  B. Kinzel,et al.  Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. , 2006, Blood.

[54]  Y. Yatomi,et al.  Sphingosine 1-phosphate in vascular biology: possible therapeutic strategies to control vascular diseases. , 2006, Current pharmaceutical design.

[55]  H. Rosen,et al.  CD69 down‐modulation and inhibition of thymic egress by short‐ and long‐term selective chemical agonism of sphingosine 1‐phosphate receptors , 2006, European journal of immunology.

[56]  S. Fernandes,et al.  Novel Insights into the Mechanism of Action of FTY720 in a Transgenic Model of Allograft Rejection: Implications for Therapy of Chronic Rejection1 , 2006, The Journal of Immunology.

[57]  C. Rosso Felipe,et al.  Immunotherapy for De Novo renal transplantation: what's in the pipeline? , 2006, Drugs.

[58]  Hugh Rosen,et al.  Lysophospholipid receptors as potential drug targets in tissue transplantation and autoimmune diseases. , 2006, Current pharmaceutical design.

[59]  E. Billy,et al.  Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. , 2006, Cancer research.

[60]  E. Hansson,et al.  Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.

[61]  V. Brinkmann,et al.  The Sphingosine 1-Phosphate Receptor Agonist FTY720 Differentially Affects the Sequestration of CD4+/CD25+ T-Regulatory Cells and Enhances Their Functional Activity , 2005, The Journal of Immunology.

[62]  R. Proia,et al.  Essential Role for Sphingosine Kinases in Neural and Vascular Development , 2005, Molecular and Cellular Biology.

[63]  M. Forrest,et al.  Sphingosine-1-Phosphate Agonists Increase Macrophage Homing, Lymphocyte Contacts, and Endothelial Junctional Complex Formation in Murine Lymph Nodes , 2005, The Journal of Immunology.

[64]  K. Chiba.  FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. , 2005, Pharmacology & therapeutics.

[65]  M. Straume,et al.  Transient T cell accumulation in lymph nodes and sustained lymphopenia in mice treated with FTY720 , 2005, European journal of immunology.

[66]  M. Koyama,et al.  FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. , 2005, Cellular & molecular immunology.

[67]  A. Thomson,et al.  The Sphingosine‐1‐Phosphate Receptor Agonist FTY720 Modulates Dendritic Cell Trafficking In Vivo , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[68]  S. Spiegel,et al.  Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling , 2005, Journal of Cell Science.

[69]  S. Dudek,et al.  Regulation of sphingosine 1‐phosphate‐induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and α‐actinin , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[70]  E. Goetzl,et al.  Type 4 sphingosine 1‐phosphate G protein‐coupled receptor (S1P4) transduces S1P effects on T cell proliferation and cytokine secretion without signaling migration , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[71]  Ying Xu,et al.  Lymphocyte Sequestration Through S1P Lyase Inhibition and Disruption of S1P Gradients , 2005, Science.

[72]  R. Förster,et al.  Sphingosine-1-Phosphate Mediates Migration of Mature Dendritic Cells1 , 2005, The Journal of Immunology.

[73]  E. Francotte,et al.  Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer. , 2005, Journal of medicinal chemistry.

[74]  E. Goetzl,et al.  Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network , 2005, Nature Reviews Immunology.

[75]  J. Chun,et al.  S1P3 receptor-induced reorganization of epithelial tight junctions compromises lung barrier integrity and is potentiated by TNF. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[76]  W. Weimar,et al.  FTY720, A Novel Immunomodulator: Efficacy and Safety Results from the First Phase 2A Study in de novo Renal Transplantation , 2005, Transplantation.

[77]  S. Payne,et al.  Expression of SphK1 impairs degranulation and motility of RBL-2H3 mast cells by desensitizing S1P receptors. , 2005, Blood.

[78]  P. Stanton,et al.  Alterations in metabolism and gap junction expression may determine the role of astrocytes as “good samaritans” or executioners , 2005, Glia.

[79]  J. Tyndall,et al.  GPCR agonists and antagonists in the clinic. , 2005, Medicinal chemistry (Shariqah (United Arab Emirates)).

[80]  J. Wess,et al.  Activation of the SPHK/S1P signalling pathway is coupled to muscarinic receptor-dependent regulation of peripheral airways , 2005, Respiratory research.

[81]  A. Monaco,et al.  Prevention and Cure of Autoimmune Diabetes in Nonobese Diabetic Mice by Continuous Administration of FTY720 , 2005, Transplantation.

[82]  Fernando Ferrer,et al.  The G protein-coupled receptor S1P2 regulates Rho/Rho kinase pathway to inhibit tumor cell migration. , 2005, Cancer research.

[83]  Michael D. Davis,et al.  Sphingosine-1-Phosphate Prevents Tumor Necrosis Factor-&agr;–Mediated Monocyte Adhesion to Aortic Endothelium in Mice , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[84]  J. Garcia,et al.  Activated Protein C Mediates Novel Lung Endothelial Barrier Enhancement , 2005, Journal of Biological Chemistry.

[85]  J. Chun,et al.  Immunomodulator FTY720 Induces eNOS-Dependent Arterial Vasodilatation via the Lysophospholipid Receptor S1P3 , 2005, Circulation research.

[86]  M. Haberal,et al.  Vascular Endothelial Growth Factor Expression and Cyclosporine Toxicity in Renal Allograft Rejection , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[87]  V. Brinkmann,et al.  The Heart Rate Decrease Caused by Acute FTY720 Administration Is Mediated by the G Protein‐Gated Potassium Channel IKACh , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[88]  S. Spiegel,et al.  The role of sphingosine-1-phosphate in smooth muscle contraction. , 2005, Cellular signalling.

[89]  L. Riboni,et al.  Extracellular release of newly synthesized sphingosine‐1‐phosphate by cerebellar granule cells and astrocytes , 2005, Journal of neurochemistry.

[90]  H. Chi,et al.  Cutting Edge: Regulation of T Cell Trafficking and Primary Immune Responses by Sphingosine 1-Phosphate Receptor 1 , 2005, The Journal of Immunology.

[91]  M. Pangalos,et al.  Edg8/S1P5: An Oligodendroglial Receptor with Dual Function on Process Retraction and Cell Survival , 2005, The Journal of Neuroscience.

[92]  Joe G. N. Garcia,et al.  In vitro and in vivo modulation of vascular barrier integrity by sphingosine 1-phosphate: mechanistic insights. , 2005, Cellular signalling.

[93]  S. Enosawa,et al.  KRP-203, a Novel Synthetic Immunosuppressant, Prolongs Graft Survival and Attenuates Chronic Rejection in Rat Skin and Heart Allografts , 2005, Circulation.

[94]  K. Adachi,et al.  Asymmetric synthesis and biological evaluation of the enantiomeric isomers of the immunosuppressive FTY720-phosphate. , 2005, Bioorganic & medicinal chemistry.

[95]  K. Rottner,et al.  Actin polymerization machinery: the finish line of signaling networks, the starting point of cellular movement , 2005, Cellular and Molecular Life Sciences CMLS.

[96]  O. Schober,et al.  High-Density Lipoprotein Stimulates Myocardial Perfusion In Vivo , 2004, Circulation.

[97]  L. Colombaioni,et al.  Sphingolipid metabolites in neural signalling and function , 2004, Brain Research Reviews.

[98]  T. Hla.  Physiological and pathological actions of sphingosine 1-phosphate. , 2004, Seminars in cell & developmental biology.

[99]  S. Davidge,et al.  Sphingosine 1‐phosphate‐induced vasoconstriction is elevated in mesenteric resistance arteries from aged female rats , 2004, British journal of pharmacology.

[100]  J. Karliner.  Mechanisms of cardioprotection by lysophospholipids , 2004, Journal of cellular biochemistry.

[101]  J. Chun,et al.  Sphingosine 1-phosphate receptor agonists attenuate relapsing–remitting experimental autoimmune encephalitis in SJL mice , 2004, Journal of Neuroimmunology.

[102]  G. Cirino,et al.  Human eosinophil chemotaxis and selective in vivo recruitment by sphingosine 1-phosphate. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[103]  R. Proia,et al.  The Sphingosine-1-phosphate Receptors S1P1, S1P2, and S1P3 Function Coordinately during Embryonic Angiogenesis* , 2004, Journal of Biological Chemistry.

[104]  J. Cyster,et al.  FTY720: Sphingosine 1‐Phosphate Receptor‐1 in the Control of Lymphocyte Egress and Endothelial Barrier Function , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[105]  S. Salomone,et al.  Vascular sphingosine-1-phosphate S1P1 and S1P3 receptors. , 2004, Drug news & perspectives.

[106]  M. Rausch,et al.  Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: Clinical implications for ultrasmall superparamagnetic iron oxide‐enhanced magnetic resonance imaging , 2004, Journal of magnetic resonance imaging : JMRI.

[107]  E. Goetzl,et al.  Physiological sphingosine 1‐phosphate requirement for optimal activity of mouse CD4+25+ regulatory T Cells , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[108]  H. Rabb,et al.  Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. , 2004, American journal of respiratory and critical care medicine.

[109]  H. Kiyono,et al.  Therapeutic Effects of a New Lymphocyte Homing Reagent FTY720 in Interleukin-10 Gene-deficient Mice with Colitis , 2004, Inflammatory bowel diseases.

[110]  R. Proia,et al.  Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes , 2004, Journal of Pharmacology and Experimental Therapeutics.

[111]  K. Murthy,et al.  Distinctive G protein-dependent signaling in smooth muscle by sphingosine 1-phosphate receptors S1P1 and S1P2. , 2004, American journal of physiology. Cell physiology.

[112]  R. Proia,et al.  Expression of the Sphingosine 1-Phosphate Receptor, S1P1, on T-cells Controls Thymic Emigration* , 2004, Journal of Biological Chemistry.

[113]  R. Proia,et al.  Transactivation of Sphingosine-1–Phosphate Receptors by FcɛRI Triggering Is Required for Normal Mast Cell Degranulation and Chemotaxis , 2004, The Journal of experimental medicine.

[114]  M. Parenti,et al.  G-protein coupled receptors in lipid rafts and caveolae: how, when and why do they go there? , 2004, Journal of molecular endocrinology.

[115]  J. Tamargo,et al.  Pharmacology of Cardiac Potassium Channels , 2003 .

[116]  K. Budde,et al.  FTY720 exerts differential effects on CD4+ and CD8+ T-lymphocyte subpopulations expressing chemokine and adhesion receptors. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[117]  G. Assmann,et al.  HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. , 2004, The Journal of clinical investigation.

[118]  S. David,et al.  Cytosolic Phospholipase A2 Plays a Key Role in the Pathogenesis of Multiple Sclerosis-like Disease , 2004, Neuron.

[119]  R. Proia,et al.  Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 , 2004, Nature.

[120]  E. Goetzl,et al.  The immunosuppressant FTY720 down‐regulates sphingosine 1‐phosphate G protein‐coupled receptors , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[121]  S. Spiegel,et al.  Lysophospholipid Receptors in the Nervous System , 2002, Neurochemical Research.

[122]  R. Pabst,et al.  Distribution of lymphocyte subsets and natural killer cells in the human body , 1992, The clinical investigator.

[123]  R. Proia,et al.  Constitutive expression of the S1P1 receptor in adult tissues. , 2004, Prostaglandins & other lipid mediators.

[124]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[125]  S. Karlik,et al.  VEGF and vascular changes in chronic neuroinflammation. , 2003, Journal of autoimmunity.

[126]  K. Claffey,et al.  Phosphorylation and Action of the Immunomodulator FTY720 Inhibits Vascular Endothelial Cell Growth Factor-induced Vascular Permeability* , 2003, Journal of Biological Chemistry.

[127]  R. Proia,et al.  G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. , 2003, Blood.

[128]  S. Traynelis,et al.  Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. , 2003, Molecular pharmacology.

[129]  D. Payan,et al.  Systematic identification of regulatory proteins critical for T-cell activation , 2003, Journal of biology.

[130]  T. Michel,et al.  VEGF induces S1P1 receptors in endothelial cells: Implications for cross-talk between sphingolipid and growth factor receptors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[131]  H. Rosen,et al.  Rapid induction of medullary thymocyte phenotypic maturation and egress inhibition by nanomolar sphingosine 1-phosphate receptor agonist , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[132]  F. Sallusto,et al.  Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. , 2003, Blood.

[133]  T. Michel,et al.  Sphingosine 1-phosphate and control of vascular tone. , 2003, American journal of physiology. Heart and circulatory physiology.

[134]  M. Moskowitz,et al.  S1P3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate. , 2003, European journal of pharmacology.

[135]  J. Kehrl,et al.  The aorta and heart differentially express RGS (regulators of G-protein signalling) proteins that selectively regulate sphingosine 1-phosphate, angiotensin II and endothelin-1 signalling. , 2003, The Biochemical journal.

[136]  T. Ohmori,et al.  Sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2. , 2003, Cardiovascular research.

[137]  H. Amemiya,et al.  Amelioration of Experimental Autoimmune Encephalomyelitis in Lewis Rats by FTY720 Treatment , 2003, Journal of Pharmacology and Experimental Therapeutics.

[138]  R. Bronson,et al.  Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. , 2003, The Journal of clinical investigation.

[139]  K. Terai,et al.  Edg-8 receptors are preferentially expressed in oligodendrocyte lineage cells of the rat CNS , 2003, Neuroscience.

[140]  M. Maceyka,et al.  Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. , 2002, Biochimica et biophysica acta.

[141]  A. Ortiz,et al.  Role of Endogenous Vascular Endothelial Growth Factor in Tubular Cell Protection Against Acute Cyclosporine Toxicity1 , 2002, Transplantation.

[142]  E. Goetzl,et al.  Activation‐regulated expression and chemotactic function of sphingosine 1‐phosphate receptors in mouse splenic T cells , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[143]  V. Brinkmann,et al.  Oral efficacy of the new immunomodulator FTY720 in cynomolgus monkey kidney allotransplantation, given alone or in combination with cyclosporine or RAD , 2002, Transplantation.

[144]  V. Brinkmann,et al.  FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. , 2002, Current opinion in immunology.

[145]  A. Zimmermann,et al.  Effects of immunosuppressant FTY720 on renal and hepatic hemodynamics in the rat , 2002, Transplantation.

[146]  S. Milstien,et al.  The roles of sphingosine-1-phosphate in asthma. , 2002, Molecular immunology.

[147]  C. Caramelo,et al.  Role of Vascular Endothelial Growth Factor , 2002 .

[148]  James R. Van Brocklyn,et al.  Sphingosine-1-phosphate stimulates human glioma cell proliferation through Gi-coupled receptors: role of ERK MAP kinase and phosphatidylinositol 3-kinase β , 2002 .

[149]  G. Nixon,et al.  Comparison of Sphingosine 1-Phosphate–Induced Intracellular Signaling Pathways in Vascular Smooth Muscles: Differential Role in Vasoconstriction , 2002, Circulation research.

[150]  J. Chun,et al.  Marked Perinatal Lethality and Cellular Signaling Deficits in Mice Null for the Two Sphingosine 1-Phosphate (S1P) Receptors, S1P2/LPB2/EDG-5 and S1P3/LPB3/EDG-3* , 2002, The Journal of Biological Chemistry.

[151]  Michael D. Davis,et al.  The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors* , 2002, The Journal of Biological Chemistry.

[152]  Kevin R. Lynch,et al.  International Union of Pharmacology. XXXIV. Lysophospholipid Receptor Nomenclature , 2002, Pharmacological Reviews.

[153]  W. Siess.  Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate. , 2002, Biochimica et biophysica acta.

[154]  F. Okajima.  Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator? , 2002, Biochimica et biophysica acta.

[155]  R. Proia,et al.  Sphingosine-1-phosphate receptors and the development of the vascular system. , 2002, Biochimica et biophysica acta.

[156]  Y. Takuwa.  Subtype-specific differential regulation of Rho family G proteins and cell migration by the Edg family sphingosine-1-phosphate receptors. , 2002, Biochimica et biophysica acta.

[157]  S. Milstien,et al.  Sphingosine-1-phosphate and lipid phosphohydrolases. , 2002, Biochimica et biophysica acta.

[158]  T. Hla,et al.  Signaling of sphingosine-1-phosphate via the S1P/EDG-family of G-protein-coupled receptors. , 2002, Biochimica et biophysica acta.

[159]  D. Mazurais,et al.  Cell Type-specific Localization of Human Cardiac S1P Receptors , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[160]  A. Fujimura,et al.  Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. , 2002, The Journal of rheumatology.

[161]  F. Di Virgilio,et al.  Sphingosine 1‐phosphate induces Chemotaxis of immature dendritic cells and modulates cytokine‐release in mature human dendritic cells for emergence of Th2 immune responses , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[162]  H. Rosen,et al.  Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists , 2002, Science.

[163]  N. Ichimaru,et al.  Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. , 2002, Cancer research.

[164]  S. Chae,et al.  Extracellular Export of Sphingosine Kinase-1 Enzyme , 2002, The Journal of Biological Chemistry.

[165]  M. Yamada.  The role of muscarinic K(+) channels in the negative chronotropic effect of a muscarinic agonist. , 2002, The Journal of pharmacology and experimental therapeutics.

[166]  B. Friedman,et al.  Selective Loss of Sphingosine 1-Phosphate Signaling with No Obvious Phenotypic Abnormality in Mice Lacking Its G Protein-coupled Receptor, LPB3/EDG-3* , 2001, The Journal of Biological Chemistry.

[167]  S. Roper,et al.  An essential role for the H218/AGR16/Edg‐5/LPB2 sphingosine 1‐phosphate receptor in neuronal excitability , 2001, The European journal of neuroscience.

[168]  J. Glowinski,et al.  Sphingosine‐1‐phosphate induces proliferation of astrocytes: regulation by intracellular signalling cascades , 2001, The European journal of neuroscience.

[169]  S. Spiegel,et al.  Sphingosine 1‐phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[170]  A. Matsumori,et al.  Therapeutic effects of FTY720, a new immunosuppressive agent, in a murine model of acute viral myocarditis. , 2001, Journal of the American College of Cardiology.

[171]  L. Pott,et al.  Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: a possible role in regulating cardiac function via sphingolipid receptors. , 2001, The Biochemical journal.

[172]  Sylvia Wong,et al.  Nrg-1 Belongs to the Endothelial Differentiation Gene Family of G Protein-coupled Sphingosine-1-phosphate Receptors* , 2001, The Journal of Biological Chemistry.

[173]  Z. Nikolova,et al.  Combined FTY720/cyclosporine A treatment promotes graft survival and lowers the peripheral lymphocyte count in DA to lewis heart and skin transplantation models. , 2001, Transplant immunology.

[174]  V. Brinkmann,et al.  FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression. , 2001, Transplantation proceedings.

[175]  M. Ui,et al.  Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. , 2000, The Biochemical journal.

[176]  O. Volpert,et al.  Sphingosine 1‐phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[177]  Y. Jan,et al.  Heartfelt crosstalk: desensitization of the GIRK current , 2000, Nature Cell Biology.

[178]  T. Imayoshi,et al.  Effect of FTY720, a novel immunosuppressant, on adjuvant-induced arthritis in rats , 2000, Inflammation Research.

[179]  S. Pyne,et al.  Sphingosine 1-phosphate signalling in mammalian cells , 2000 .

[180]  R. Zinkernagel,et al.  FTY720 Immunosuppression Impairs Effector T Cell Peripheral Homing Without Affecting Induction, Expansion, and Memory1 , 2000, The Journal of Immunology.

[181]  B. O'dowd,et al.  Characterization of a Novel Sphingosine 1-Phosphate Receptor, Edg-8* , 2000, The Journal of Biological Chemistry.

[182]  T. Imayoshi,et al.  Effect of FTY720, a novel immunosuppressant, on adjuvant- and collagen-induced arthritis in rats. , 2000, International journal of immunopharmacology.

[183]  M. Isobe,et al.  FTY720 prevents development of experimental autoimmune myocarditis through reduction of circulating lymphocytes. , 2000, Journal of cardiovascular pharmacology.

[184]  L. Feng,et al.  FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation. , 2000, Trends in pharmacological sciences.

[185]  M. Mochizuki,et al.  Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats. , 2000, Experimental eye research.

[186]  D. Laskin,et al.  Nitric oxide in the lung: therapeutic and cellular mechanisms of action. , 1999, Pharmacology & therapeutics.

[187]  Y. G. Kwon,et al.  Sphingosine 1-phosphate induces angiogenesis: its angiogenic action and signaling mechanism in human umbilical vein endothelial cells. , 1999, Biochemical and biophysical research communications.

[188]  F. Sallusto,et al.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.

[189]  W. Giles,et al.  Effects of sphingosine 1-phosphate on pacemaker activity in rabbit sino-atrial node cells , 1999, Pflügers Archiv.

[190]  Renae L. Malek,et al.  Molecular Cloning, Tissue-Specific Expression, and Chromosomal Localization of a Novel Nerve Growth Factor-Regulated G-Protein-Coupled Receptor, nrg-1 , 1999, Molecular and Cellular Neuroscience.

[191]  T. Baumruker,et al.  The Balance between Sphingosine and Sphingosine-1-phosphate Is Decisive for Mast Cell Activation after Fc ⑀ Receptor I Triggering , 1999 .

[192]  E. Goetzl,et al.  Lysophosphatidic acid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of Bax. , 1999, Journal of immunology.

[193]  M. Lipp,et al.  A lymphoid tissue-specific receptor, EDG6, with potential immune modulatory functions mediated by extracellular lysophospholipids. , 1999, Current topics in microbiology and immunology.

[194]  Y. Yatomi,et al.  EDG1 Is a Functional Sphingosine-1-phosphate Receptor That Is Linked via a Gi/o to Multiple Signaling Pathways, Including Phospholipase C Activation, Ca2+Mobilization, Ras-Mitogen-activated Protein Kinase Activation, and Adenylate Cyclase Inhibition* , 1998, The Journal of Biological Chemistry.

[195]  M. Lipp,et al.  EDG6, a novel G-protein-coupled receptor related to receptors for bioactive lysophospholipids, is specifically expressed in lymphoid tissue. , 1998, Genomics.

[196]  Y. Igarashi,et al.  Exogenous sphingosine 1-phosphate induces neurite retraction possibly through a cell surface receptor in PC12 cells. , 1997, Biochemical and biophysical research communications.

[197]  Shuh Narumiya,et al.  Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension , 1997, Nature.

[198]  K. Jalink,et al.  Sphingosine‐1‐phosphate rapidly induces Rho‐dependent neurite retraction: action through a specific cell surface receptor. , 1996, The EMBO journal.

[199]  K. Jakobs,et al.  Activation of muscarinic K+ current in guinea‐pig atrial myocytes by sphingosine‐1‐phosphate. , 1995, The Journal of physiology.

[200]  T. Fujita,et al.  Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: Discovery of a novel immunosuppressant, FTY720 , 1995 .

[201]  T. Hla,et al.  An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein-coupled receptors. , 1990, The Journal of biological chemistry.